The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international group.

Auteurs : Maetens M, Brown D, Irrthum A, Aftimos P, Viale G, Loibl S, Laes JF, Campbell PJ, Thompson A, Cortes J, Seiler S, Vinnicombe S, Oliveira M, Rothé F, Bareche Y, Fumagalli D, Zardavas D, Desmedt C, Piccart-Gebhart M, Loi S, Sotiriou C
Année : 2017
Journal : NPJ Breast Cancer
Volume : 3
Pages : 23

Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper.

Auteurs : Aapro M, Astier A, Audisio R, Banks I, Bedossa P, Brain E, Cameron D, Casali P, Chiti A, De Mattos-Arruda L, Kelly D, Lacombe D, Nilsson PJ, Piccart M, Poortmans P, Riklund K, Saeter G, Schrappe M, Soffietti R, Travado L, Van Poppel H, Wait S, Naredi P
Année : 2017
Journal : Eur J Cancer
Volume : 82
Pages : 193-202

Unusual presentation of nasopharyngeal carcinoma with rectal metastasis.

Auteurs : Vogel M, Kourie HR, Piccart-Gebhart M, Lalami Y
Année : 2017
Journal : World J Clin Cases
Volume : 5
Pages : 183-186

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib.

Auteurs : Raspé E, Coulonval K, Pita JM, Paternot S, Rothé F, Twyffels L, Brohée S, Craciun L, Larsimont D, Kruys V, Sandras F, Salmon I, Van Laere S, Piccart-Gebhart M, Ignatiadis M, Sotiriou C, Roger PP
Année : 2017
Journal : EMBO Mol Med
Volume : 9
Pages : 1052-1066

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

Auteurs : Von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber Rd, Piccart-Gebhart M, Baselga J
Année : 2017
Journal : N Engl J Med
Volume : 377(2)
Pages : 122-131

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

Auteurs : Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Pernault-Llorca F, Piccart-Gebhart M, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E
Année : 2017
Journal : Ann Oncol
Volume : 28(1)
Pages : 16-33

3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).

Auteurs : Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Pernault-Llorca F, Piccart-Gebhart M, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E
Année : 2017
Journal : Breast
Volume : 31
Pages : 244-259

RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.

Auteurs : Fumagalli D, Venet D, Ignatiadis M, Azim HA Jr, Maetens M, Rothé F, Salgado R, Bradbury I, Pusztai L, Harbeck N, Gomez H, Chang TW, Coccia-Portugal MA, Di Cosimo S, de Azambuja E, de la Peña L, Nuciforo P, Brase JC, Huober J, Baselga J, Piccart-Gebhart M, Loi S, Sotiriou C
Année : 2017
Journal : JAMA Oncol
Volume : 3
Pages : 227-234

Cancer drugs, survival and ethics: a critical look from the inside.

Auteurs : Piccart-Gebhart M, Pondé N
Année : 2016
Journal : ESMO Open
Volume : 1
Pages : e000149

The European Cancer Patient's Bill of Rights, update and implementation 2016.

Auteurs : Højgaard L, Löwenberg B, Selby P, Lawler M, Banks I, Law K, Albreht T, Armand JP, Barbacid M, Barzach M, Bergh J, Cameron D, Conte P, de Braud F, de Gramont A, de Lorenzo F, Diehl V, Diler S, Erdem S, Geissler J, Gore-Booth J, Henning G, Horgan D, Jassem J, Johnson P, Kaasa S, Kapitein P, Karjalainen S, Kelly J, Kienesberger A, La Vecchia C, Lacombe D, Lindahl T, Luzzatto L, Malby R, Mastris K, Meunier F, Murphy M, Naredi P, Nurse P, Oliver K, Pearce J, Pelouchov J, Piccart-Gebhart M, Pinedo B, Spurrier-Bernard G, Sullivan R, Tabernero J, van de Velde C, van Herk B, Vedsted P, Waldmann A, Weller D, Wilking N, Wilson R, Yared W, Zielinski C, Zur Hausen H, Le Chevalier T, Johnston P
Année : 2016
Journal : ESMO Open
Volume : 1
Pages : e000127

Reply to the letter to the editor 'The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice' by Hartmann and the letter 'Comment on ESMO Magnitude of Clinical Benefit Scale' by Muhonen et al.

Auteurs : Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EGE, Piccart-Gebhart M
Année : 2016
Journal : Ann Oncol
Volume : 27
Pages : 205-207

Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer.

Auteurs : Buisseret L, Garaud S, de Wind A, Van den Eynden G, Boisson A, Solinas C, Gu-Trantien C, Naveaux C, Lodewyckx JN, Duvillier H, Craciun L, Veys I, Larsimont D, Piccart-Gebhart M, Stagg J, Sotiriou C, Willard-Gallo K
Année : 2016
Journal : Oncoimmunology
Volume : 6
Pages : e1257452

70-Gene Signature in Early-Stage Breast Cancer.

Auteurs : van’t Veer LJ, Rutgers EJT, Piccart-Gebhart M
Année : 2016
Journal : N Engl J Med
Volume : 375
Pages : 2200-2201

Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards.

Auteurs : Bottomley A, Pe M, Sloan J, Basch E, Bonnetain F, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Greimel E, Griebsch I, Groenvold M, Hamel JF, King M, Kluetz PG, Koller M, Malone DC, Martinelli F, Mitchell SA, Moinpour CM, Musoro J, OConnor D, Oliver K, Piault-Louis E, Piccart-Gebhart M, Pimentel FL, Quinten C, Reijneveld JC, Schürmann C, Smith AW, Soltys KM, Taphoorn MJ, Velikova G, Coens C
Année : 2016
Journal : Lancet Oncol
Volume : 17
Pages : e510-e514

Targeted adjuvant therapy in breast cancer.

Auteurs : Zardavas D, Tryfonidis K, Goulioti T, Piccart-Gebhart M
Année : 2016
Journal : Expert Rev Anticancer Ther
Volume : 16(12)
Pages : 1263-75

Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer.

Auteurs : Bense RD, Sotiriou C, Piccart-Gebhart M, Haanen JB, van Vugt MA, de Vries EG, Schröder CP, Fehrmann RS
Année : 2016
Journal : J Natl Cancer Inst
Volume : 109

Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers.

Auteurs : Fumagalli D, Wilson TR, Salgado R, Lu X, Yu J, OBrien C, Walter K, Huw LY, Criscitiello C, Laios I, Jose V, Brown DN, Rothé F, Maetens M, Zardavas D, Savas P, Larsimont D, Piccart-Gebhart M, Michiels S, Lackner MR, Sotiriou C, Loi S
Année : 2016
Journal : Ann Oncol
Volume : 27
Pages : 1860-6

Pathway level alterations rather than mutations in single genes predict response to HER2 targeted therapies in the neo-ALTTO trial.

Auteurs : Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L
Année : 2016
Journal : Ann Oncol
Volume : 28(1)
Pages : 128-35

Endocrine treatment in breast cancer: Cure, resistance and beyond.

Auteurs : Tryfonidis K, Zardavas D, Katzenellenbogen BS, Piccart-Gebhart M
Année : 2016
Journal : Cancer Treat Rev
Volume : 50
Pages : 68-81

Reply to the letter to the editor 'Utilisation of the ESMO-MCBS in practice of HTA' by Wild et al.

Auteurs : Cherny NI, Sullivan R, Dafni U, Bogaerts J, Kerst JM, Zielinski C, Piccart-Gebhart M, de Vries EG
Année : 2016
Journal : Ann Oncol
Volume : 27(11)
Pages : 2136-7